Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center
- 11 January 2007
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 25 (6) , 709-714
Abstract
In July 2001, our Veterans' Affairs hospital changed its formulary proton pump inhibitor (PPI) from lansoprazole to rabeprazole. All patients previously receiving lansoprazole 30 mg twice daily were switched to rabeprazole 20 mg once daily. To determine if patients with gastro-oesophageal reflux disease (GERD), who were previously managed on lansoprazole 30 mg twice daily, could be maintained on rabeprazole 20 mg once daily. Four hundred and thirty-five patients had received lansoprazole 30 mg twice daily for at least 12 months before the formulary change. Medical records were reviewed for 12 months before and after the formulary change. There were 432 men and three women with a mean age of 66.7 years (range: 38-91). Two hundred and twelve patients were excluded. Of the remaining 223, 111 (50%) were maintained successfully on rabeprazole 20 mg once daily. Twenty-three (10%) stayed off all acid suppression during follow-up. The number of endoscopies and clinic visits did not significantly change during the follow-up. Fifty-six percent who had erosive oesophagitis failed a dose taper compared with 31% of those with endoscopy-negative GERD (P<0.025). Most patients receiving twice daily PPI therapy for GERD could be maintained on once daily PPI or no acid suppression for 12 months of follow-up. Dose reduction was more successful in those without erosive oesophagitis.Keywords
This publication has 21 references indexed in Scilit:
- Effectiveness and Costs of Omeprazole vs Ranitidine for Treatment of Symptomatic Gastroesophageal Reflux Disease in Primary Care Clinics in West VirginiaArchives of Family Medicine, 2000
- Lansoprazole Compared With Ranitidine for the Treatment of Nonerosive Gastroesophageal Reflux DiseaseArchives of internal medicine (1960), 2000
- Efficacy of Omeprazole for the Treatment of Symptomatic Acid Reflux Disease Without EsophagitisArchives of internal medicine (1960), 2000
- Rabeprazole Versus Omeprazole in Preventing Relapse of Erosive or Ulcerative Gastroesophageal Reflux DiseaseDigestive Diseases and Sciences, 2000
- Rabeprazole, 20 mg Once Daily or 10 mg Twice Daily, Is Equivalent to Omeprazole, 20 mg Once Daily, in the Healing of Erosive Gastrooesophageal Reflux DiseaseScandinavian Journal of Gastroenterology, 2000
- Double‐blind, placebo‐controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 1999
- Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysisGastroenterology, 1997
- Lansoprazole versus Omeprazole in Short-Term Treatment of Reflux Oesophagitis Results of a Scandinavian Multicentre TrialScandinavian Journal of Gastroenterology, 1993
- Epidemiology and Natural History of Gastro-Oesophageal Reflux DiseaseDigestion, 1992
- Symptomatic gastroesophageal reflux: Incidence and precipitating factorsDigestive Diseases and Sciences, 1976